Chemotherapy-induced peripheral neuropathy: Underreported and underappreciated

Current Pain and Headache Reports

Volumn 10, Issue 4, 2006, Pages 275-278

  Markman, Maurie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; GABAPENTIN; PACLITAXEL;

CANCER PATIENT; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EXPERIENCE; HUMAN; INFORMATION SYSTEM; MALIGNANT NEOPLASTIC DISEASE; MEDICAL ASSESSMENT; MEDICAL SPECIALIST; NEUROLOGIC DISEASE; OVARY CANCER; PARESTHESIA; PATIENT ATTITUDE; PATIENT REFERRAL; PERIPHERAL NEUROPATHY; REVIEW; SKIN TINGLING; SYMPTOM; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 33746444305     PISSN: 15313433     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11916-006-0032-0     Document Type: Review

References (18)

1. Floyd JD, Nguyen DT, Lobins RL, et al.: Cardiotoxicity of cancer therapy. J Clin Oncol 2005, 23:7685-7696.
2. Kaldor JM, Day NE, Pettersson F, et al.: Leukemia following chemotherapy for ovarian cancer. N Engl J Med 1990, 322:1-6.
3. Travis LB, Holowaty EJ, Bergfeldt K, et al.: Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med 1999, 340:351-357.
4. Cavalatti G, Marzorati L, Bogliun G, et al.: Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 1992, 69:203-207.
5. Visovsky C: Chemotherapy-induced peripheral neuropathy. Cancer Invest 2003, 21:439-451.
6. Warner E: Neurotoxicity of cisplatin and taxol. Int J Gynecol Cancer 1995, 5:161-169.
7. Tuxen MK, Hansen SW: Complications of treatment: neurotoxicity to anti-neoplastic drugs. Cancer Treat Rev 1994, 20:191-214.
8. Quasthoff S, Hartung HP: Chemotherapy-induced peripheral neuropathy. J Neurol 2002, 349:9-17.
9. Peltier AC, Russell JW: Recent advanced in drug-induced neuropathies. Curr Opin Neurol 2002, 15:633-638.
10. Roberts JA, Jenison EL, Kim KM, et al.: A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol 1997, 67:172-177.
11. Mollman JE: Cisplatin neuropathy. N Engl J Med 1990, 332:126-127.
12. Moore DH, Donnelly J, McGuire WP, et al.: Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase-II study of the Gynecologic Oncology Group. J Clin Oncol 2003, 21:4207-4213.
13. Postma TJ, Heimans JJ, Muller MJ: Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 1998, 9:739-744.
14. Markman M: Limits to the "benefits" from our oncologic interventions: a case report. Gynecol Oncol 2000, 78:261-262.
15. Di Maio M, Iaffaioli RV, de Placido de S, et al.: Residual neurotoxicity in patients with ovarian cancer in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trials in Ovarian cancer (MITO-4) retrospective study. J Clin Oncol 2005, 23(suppl):458s.
16. Pace A, Savarese A, Picardo M, et al.: Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 1993, 21:927-931.
17. Argyriou AA, Chroni E, Koutras A, et al.: Vitamin E for prophylaxis against chemotherapy-induced neuropathy. Neurology 2005, 64:26-31.
18. Forman AD: Peripheral neuropathy and cancer. Curr Oncol Rep 2004, 6:20-25.